Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ROIV |
---|---|---|
09:32 ET | 21167 | 12.17 |
09:34 ET | 21902 | 12.25 |
09:36 ET | 24111 | 12.245 |
09:38 ET | 21986 | 12.26 |
09:39 ET | 9783 | 12.24 |
09:41 ET | 18819 | 12.25 |
09:43 ET | 30771 | 12.25 |
09:45 ET | 14732 | 12.265 |
09:48 ET | 22206 | 12.25 |
09:50 ET | 12775 | 12.245 |
09:52 ET | 18697 | 12.25 |
09:54 ET | 8701 | 12.24 |
09:56 ET | 20200 | 12.251 |
09:57 ET | 43323 | 12.205 |
09:59 ET | 17885 | 12.205 |
10:01 ET | 12205 | 12.175 |
10:03 ET | 16336 | 12.135 |
10:06 ET | 14845 | 12.155 |
10:08 ET | 11381 | 12.14 |
10:10 ET | 16868 | 12.16 |
10:12 ET | 22004 | 12.175 |
10:14 ET | 8321 | 12.19 |
10:15 ET | 18616 | 12.18 |
10:17 ET | 12675 | 12.18 |
10:19 ET | 10087 | 12.19 |
10:21 ET | 36205 | 12.18 |
10:24 ET | 37157 | 12.21 |
10:26 ET | 23724 | 12.21 |
10:28 ET | 14176 | 12.21 |
10:30 ET | 41894 | 12.225 |
10:32 ET | 25497 | 12.19 |
10:33 ET | 18013 | 12.19 |
10:35 ET | 7783 | 12.18 |
10:37 ET | 31163 | 12.2 |
10:39 ET | 19194 | 12.205 |
10:42 ET | 21665 | 12.205 |
10:44 ET | 7923 | 12.195 |
10:46 ET | 8390 | 12.2 |
10:48 ET | 10524 | 12.165 |
10:50 ET | 12704 | 12.155 |
10:51 ET | 10039 | 12.145 |
10:53 ET | 23254 | 12.1002 |
10:55 ET | 28047 | 12.085 |
10:57 ET | 21886 | 12.1 |
11:00 ET | 16876 | 12.095 |
11:02 ET | 13700 | 12.1 |
11:04 ET | 9818 | 12.115 |
11:06 ET | 10259 | 12.115 |
11:08 ET | 15245 | 12.115 |
11:09 ET | 6688 | 12.095 |
11:11 ET | 26865 | 12.07 |
11:13 ET | 50158 | 12.04 |
11:15 ET | 14512 | 12.025 |
11:18 ET | 64734 | 12.06 |
11:20 ET | 12944 | 12.045 |
11:22 ET | 4694 | 12.045 |
11:24 ET | 26377 | 12.06 |
11:26 ET | 9827 | 12.07 |
11:27 ET | 17141 | 12.08 |
11:29 ET | 7391 | 12.07 |
11:31 ET | 6847 | 12.055 |
11:33 ET | 8750 | 12.065 |
11:36 ET | 2155 | 12.07 |
11:38 ET | 22382 | 12.075 |
11:40 ET | 16181 | 12.07 |
11:42 ET | 17531 | 12.09 |
11:44 ET | 8897 | 12.1 |
11:45 ET | 10421 | 12.085 |
11:47 ET | 3983 | 12.085 |
11:49 ET | 2473 | 12.09 |
11:51 ET | 48883 | 12.06 |
11:54 ET | 21912 | 12.065 |
11:56 ET | 25200 | 12.063 |
11:58 ET | 14264 | 12.045 |
12:00 ET | 14868 | 12.055 |
12:02 ET | 20379 | 12.055 |
12:03 ET | 4199 | 12.06 |
12:05 ET | 1228 | 12.055 |
12:07 ET | 15026 | 12.045 |
12:09 ET | 3453 | 12.045 |
12:12 ET | 15536 | 12.045 |
12:14 ET | 11769 | 12.06 |
12:16 ET | 11513 | 12.04 |
12:18 ET | 75663 | 12.0847 |
12:20 ET | 4320 | 12.08 |
12:21 ET | 18690 | 12.08 |
12:23 ET | 3982 | 12.07 |
12:25 ET | 24418 | 12.045 |
12:27 ET | 11581 | 12.0301 |
12:30 ET | 21727 | 12.045 |
12:32 ET | 11041 | 12.035 |
12:34 ET | 12274 | 12.02 |
12:36 ET | 23670 | 12.005 |
12:38 ET | 28034 | 11.98 |
12:39 ET | 13587 | 11.97 |
12:41 ET | 65208 | 11.97 |
12:43 ET | 19184 | 11.96 |
12:45 ET | 33509 | 11.96 |
12:48 ET | 27331 | 11.995 |
12:50 ET | 1949 | 11.9949 |
12:52 ET | 12039 | 11.985 |
12:54 ET | 5565 | 11.985 |
12:56 ET | 26760 | 11.99 |
12:57 ET | 5268 | 11.975 |
12:59 ET | 8435 | 11.985 |
01:01 ET | 55398 | 12.005 |
01:03 ET | 24485 | 12.02 |
01:06 ET | 9662 | 12.04 |
01:08 ET | 2811 | 12.035 |
01:10 ET | 8053 | 12.02 |
01:12 ET | 5211 | 12.02 |
01:14 ET | 25159 | 12.001 |
01:15 ET | 7796 | 12 |
01:17 ET | 49868 | 12.01 |
01:19 ET | 2446 | 12.015 |
01:21 ET | 1433 | 12.015 |
01:24 ET | 10604 | 11.995 |
01:26 ET | 18625 | 12.025 |
01:28 ET | 2782 | 12.025 |
01:30 ET | 9517 | 12.025 |
01:32 ET | 9208 | 12.015 |
01:33 ET | 24794 | 12.02 |
01:35 ET | 6713 | 12.01 |
01:37 ET | 3087 | 12.015 |
01:39 ET | 15845 | 12.02 |
01:42 ET | 14772 | 12.02 |
01:44 ET | 46633 | 12.02 |
01:46 ET | 9170 | 12.02 |
01:48 ET | 9360 | 12.02 |
01:50 ET | 36212 | 12.025 |
01:51 ET | 12289 | 12.035 |
01:53 ET | 15620 | 12.05 |
01:55 ET | 4060 | 12.055 |
01:57 ET | 13176 | 12.055 |
02:00 ET | 9439 | 12.04 |
02:02 ET | 19388 | 12.025 |
02:04 ET | 17809 | 12.04 |
02:06 ET | 2290 | 12.045 |
02:08 ET | 9482 | 12.05 |
02:09 ET | 32835 | 12.055 |
02:11 ET | 1900 | 12.06 |
02:13 ET | 17120 | 12.065 |
02:15 ET | 2601 | 12.065 |
02:18 ET | 9356 | 12.06 |
02:20 ET | 11785 | 12.075 |
02:22 ET | 4268 | 12.075 |
02:24 ET | 4616 | 12.075 |
02:26 ET | 17016 | 12.06 |
02:27 ET | 26097 | 12.06 |
02:29 ET | 2910 | 12.055 |
02:31 ET | 7800 | 12.055 |
02:33 ET | 5099 | 12.055 |
02:36 ET | 24900 | 12.08 |
02:38 ET | 13256 | 12.065 |
02:40 ET | 13477 | 12.075 |
02:42 ET | 4093 | 12.075 |
02:44 ET | 10957 | 12.085 |
02:45 ET | 4825 | 12.085 |
02:47 ET | 18466 | 12.105 |
02:49 ET | 25907 | 12.1 |
02:51 ET | 3344 | 12.095 |
02:54 ET | 12448 | 12.085 |
02:56 ET | 23027 | 12.09 |
02:58 ET | 32634 | 12.07 |
03:00 ET | 17167 | 12.055 |
03:02 ET | 12432 | 12.035 |
03:03 ET | 15751 | 12.015 |
03:05 ET | 2576 | 12.01 |
03:07 ET | 12976 | 12 |
03:09 ET | 5528 | 11.995 |
03:12 ET | 3577 | 11.99 |
03:14 ET | 39565 | 11.98 |
03:16 ET | 55021 | 12.005 |
03:18 ET | 72557 | 12.011 |
03:20 ET | 118136 | 12.015 |
03:21 ET | 79404 | 11.995 |
03:23 ET | 13289 | 12.005 |
03:25 ET | 2648 | 12.005 |
03:27 ET | 4921 | 12.006 |
03:30 ET | 21522 | 12 |
03:32 ET | 28757 | 12.015 |
03:34 ET | 21143 | 12 |
03:36 ET | 16146 | 12.015 |
03:38 ET | 23010 | 12.005 |
03:39 ET | 16767 | 11.99 |
03:41 ET | 10353 | 11.985 |
03:43 ET | 32742 | 11.98 |
03:45 ET | 27108 | 11.975 |
03:48 ET | 104349 | 11.94 |
03:50 ET | 64602 | 11.95 |
03:52 ET | 233860 | 11.945 |
03:54 ET | 95342 | 11.93 |
03:56 ET | 240931 | 11.935 |
03:57 ET | 98433 | 11.935 |
03:59 ET | 1456403 | 11.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Roivant Sciences Ltd | 8.8B | 2.1x | --- |
Ligand Pharmaceuticals Inc | 1.9B | 47.1x | -12.71% |
Corcept Therapeutics Inc | 4.0B | 33.5x | +9.80% |
Harrow Inc | 1.6B | -47.5x | --- |
Ocular Therapeutix Inc | 1.4B | -8.2x | --- |
Immunocore Holdings PLC | 1.7B | -31.3x | --- |
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its pipeline program also includes Mosliciguat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.8B |
---|---|
Revenue (TTM) | $158.3M |
Shares Outstanding | 739.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $5.57 |
Book Value | $7.40 |
P/E Ratio | 2.1x |
Price/Sales (TTM) | 55.8 |
Price/Cash Flow (TTM) | 1.9x |
Operating Margin | 2,799.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.